



<b>MONDAY</b>	<b>Session</b>	<b>Content</b>
9:00-9:30	G41	Registration (tea and coffee)
9:30-10:15	<b>Session 0</b> Manson	<a href="#">Introduction and logistics</a> Claudia Allemani/Michel Coleman
10:15-11:00	<b>Session 1</b> Manson	<a href="#">Cancer survival research and cancer policy - 1</a> Michel Coleman
11:00-11:30	G41	Refreshment break
11:30-12:15	<b>Session 2</b> Manson	<a href="#">Population-based measures of the cancer burden</a> Eman Alkhalawi
12:15-13:00	<b>Session 3</b> Manson	<a href="#">Introduction to survival analysis</a> Veronica Di Carlo
13:00-14:15	G41	Welcome lunch
14:15-15:00	<b>Session 4</b> Manson	<a href="#">Population-based cancer survival: concepts</a> Claudia Allemani
15:00-15:30	G41	Refreshment break
15:30-16:30	<b>Session 5</b> G41	<a href="#">Practical 1: Set-up, introduction and downloads</a> Participants and faculty
16:30-17:30	<b>Session 6</b> G41	<a href="#">Practical 2: Estimating cancer survival</a> Participants and faculty
17:30-18:00	<b>Session 7</b> G41	<a href="#">Questions and answers from Day 1</a> Participants and faculty
<b>TUESDAY</b>	<b>Session</b>	<b>Content</b>
9:00-10:30	<b>Session 8</b> Manson	<a href="#">Relative survival analysis</a> Maja Pohar Perme
10:30-11:00	G41	Refreshment break

11:00-12:30	<b>Session 9</b> Manson	<a href="#">Population-based cancer survival: data quality and quality control</a> Claudia Allemani
12:30-13:30	-	Lunch break (on your own)
13:30-14:15	<b>Session 10</b> Manson	<a href="#">Age-standardisation of cancer survival</a> Fatima Khan Baloch
14:15-15:15	<b>Session 11</b> Manson	<a href="#">Life tables of background mortality and their impact on survival estimates</a> Veronica Di Carlo
15:15-15:45	G41	Refreshment break
15:45-17:15	<b>Session 12</b> G41	<a href="#">Practical 3: Net survival estimation, and the impact of life tables of background mortality on the estimates</a> Participants and faculty
17:15-18:00	<b>Session 13</b> G41	<a href="#">Questions and answers from Day 2</a> Participants and faculty

## **WEDNESDAY**   **Session**   **Content**

9:00-10:30	<b>Session 14</b> Manson	<a href="#">Period analysis and “prediction” of survival</a> Naomi Ssenyonga
10:30-11:00	G41	Refreshment break
11:00-12:30	<b>Session 15</b> G41	<a href="#">Practical 4: Period analysis and “prediction” of survival</a> Participants and faculty
12:30-13:45	-	Lunch break (on your own)
13:45-15:00	<b>Session 16</b> Manson	<a href="#">Modelling net survival</a> Maja Pohar Perme and Paul Dickman
15:00-15:45	Course photo (front steps), then refreshment break (G41)	
15:45-17:15	<b>Session 17</b> G41	<a href="#">Practical 5: Modelling net survival</a> Participants and faculty
17:15-18:00	<b>Session 18</b> G41	<a href="#">Questions and answers from Day 3</a> Participants and faculty

THURSDAY	Session	Content
9:00-10:30	<b>Session 19</b> Manson	<a href="#">Non-parametric estimation and modelling in relative survival</a> Maja Pohar Perme
10:30-11:00	G41	Refreshment break
11:00-12:30	<b>Session 20</b> Manson	<a href="#">Statistical “cure”</a> Saverio Virdone
12:30-13:45	-	Lunch break (on your own)
13:45-15:15	<b>Session 21</b> G41	<a href="#">Practical 6: Modelling statistical “cure”</a> Participants and faculty
15:15-15:45	G41	Refreshment break
15:45-16:45	<b>Session 22</b> Manson	<a href="#">Cancer survival – participants’ case studies</a> Facilitated by Marisa Sophiea
16:45-17:45	<b>Session 23</b> Manson	<a href="#">Questions and answers from Day 4</a> Participants and faculty
FRIDAY	Session	Content
9:00-10:00	<b>Session 24</b> Manson	<a href="#">Recent advances in cancer treatment</a> Fabio Girardi
10:00-11:00	<b>Session 25</b> Manson	<a href="#">Mortality-to-incidence ratio: not a valid proxy for cancer survival</a> Michel Coleman
11:00-11:30	G41	Refreshment break
11:30-13:00	<b>Session 26</b> Manson	<a href="#">International comparisons of cancer survival</a> Claudia Allemani
13:00-14:00	G41	Farewell lunch
14:00-15:15	<b>Session 27</b> Manson	<a href="#">Cancer survival research and cancer policy - 2</a> Michel Coleman
15:15-15:30	<b>Session 28</b> Manson	<a href="#">Tools for survival analysis</a> Participants and faculty
15:30-16:00	<b>Session 29</b> Manson	<a href="#">Closing session</a>

## Outline of the contents of each session

### Session 0

#### Introduction and logistics

- Objectives of the course
- Introduction of faculty members
- Outline of course structure
- Presentation of course materials
- Announcements

[Back](#)

### Session 1

#### Cancer survival research and cancer policy – 1

- Why do we study cancer survival? An introduction to the wider public health and health policy applications
- The public interest and communication with the public
- Evaluation of cancer treatment and cancer survival in the population setting
- Evaluation of cancer control policy

[Back](#)

### Session 2

#### Population-based measures of the cancer burden

- Introduction to the concept of the cancer burden
- The need for population-based cancer registry data for incidence and survival
- Principles of population-based measures of the cancer burden
- Review of incidence, prevalence and mortality metrics
- Introduction to survival
- Relationship between measures of the cancer burden

[Back](#)

### Session 3

#### Introduction to survival analysis

- Introduction to time-to-event data
- Definition of the survival and hazard functions
- Actuarial and Kaplan-Meier methods for estimation of the survival function

[Back](#)

### Session 4

#### Population-based cancer survival: concepts

- Definition of all-cause survival
- Definition of net survival
- Introduction to the cause-specific survival setting
- Introduction to the relative survival setting

[Back](#)

## **Session 5**

### **Practical 1 – Set-up, introduction and downloads**

- This session will include an introduction to Stata and setting up for practicals 2-6
- The session will be led by one of the course faculty, and other faculty members will be available to provide assistance

[Back](#)

## **Session 6**

### **Practical 2 – Estimating cancer survival**

- In this session, you will have the opportunity to do practical exercises based on the themes discussed in the accompanying lecture. A practical leader will facilitate the session, and faculty members will provide assistance. Solutions will be provided during the session.

[Back](#)

## **Session 7**

### **Questions and answers from Day 1**

- An informal question-and-answer session on any topic covered on the first day. All participants and faculty will be invited to contribute

[Back](#)

## **Session 8**

### **Relative survival analysis**

- Introduction to competing risks analysis
- The various concepts in relative survival: overall survival, crude mortality, net survival, relative survival ratio
- Non-parametric estimators of relative survival measures
- Specific aspects of estimation

[Back](#)

## **Session 9**

### **Population-based cancer survival: data quality and quality control**

- Data quality and quality control: an essential component of epidemiological research
- Background to population-based cancer registration: regional and national registries, general and specialised registries
- Registration systems: sources of data; active and passive follow-up
- Purpose of data quality indicators for cancer survival
  - ✓ to document data quality for external review
  - ✓ to ensure robust comparisons of survival
- Types of quality control:
  - ✓ on each variable (compliance with the study protocol)
  - ✓ on each record (logical coherence of variables)
  - ✓ on each data set (frequency distributions, summary measures, ...)
- Improving comparability through standard approaches to coding of topography, morphology and stage

[Back](#)

## **Session 10**

### **Age-standardisation of cancer survival**

- Importance of age standardisation
- Age-standardisation methods
- Examples of application and interpretation of age-standardised estimates
- Choice of standard weights
- Extension to multi-factor standardisation, e.g., a cancer survival index

[Back](#)

## **Session 11**

### **Life tables of background mortality and their impact on survival estimates**

- Life tables – an historical note
- Description of main indicators
- Smoothing techniques – from abridged to complete life tables
- Life tables for population sub-groups
- Role of life tables in the estimation of net survival

[Back](#)

## **Session 12**

### **Practical 3 – Net survival estimation, and the impact of life tables of background mortality on the estimates**

- In this session, you will have the opportunity to do practical exercises based on the themes discussed in the accompanying lecture. A practical leader will facilitate the session, and faculty members will provide assistance. Solutions will be provided during the session.

[Back](#)

## **Session 13**

### **Questions and Answers from Day 2**

- An informal question-and-answer session on any topic covered on the second day. All participants and faculty will be invited to contribute.

[Back](#)

## **Session 14**

### **Period analysis and “prediction” of survival**

- Cohort, complete and period approaches to cancer survival analysis
- Principles and theoretical basis of period analysis: analogy with expectation of life
- Application and interpretation of period survival estimates
- Developments in period analysis, including hybrid analysis

[Back](#)

## **Session 15**

### **Practical 4 – Period analysis and “prediction” of survival**

- In this session, you will have the opportunity to do practical exercises based on the themes discussed in the accompanying lecture. A practical leader will facilitate the session, and faculty members will provide assistance. Solutions will be provided during the session.

[Back](#)

## **Session 16**

### **Modelling net survival**

- The outcome in survival analysis can be expressed either as a survival proportion or as a mortality rate (hazard)
- Net mortality can be estimated and modelled in a cause-specific or relative survival framework. We model on the hazard scale; cause-specific or excess.
- Three modelling approaches will be presented, and their close similarities highlighted. Cox regression, Poisson regression, and flexible parametric models. The latter two can be used to model both cause-specific and excess mortality, whereas Cox regression cannot.
- The three approaches are conceptually very similar
- The proportional hazards assumption

[Back](#)

## **Session 17**

### **Practical 5 – Modelling net survival**

- In this session, you will have the opportunity to do practical exercises based on the themes discussed in the accompanying lecture. A practical leader will facilitate the session, and faculty members will provide assistance. Solutions will be provided during the session.

[Back](#)

## **Session 18**

### **Questions and answers from Day 3**

- An informal question-and-answer session on any topic covered on the third day. All participants and faculty will be invited to contribute.

[Back](#)

## **Session 19**

### **Non-parametric estimation and modelling in relative survival**

- The link between non-parametric estimation and modelling
- Specific issues and pitfalls of relative survival

[Back](#)

## **Session 20**

### **Statistical “cure”**

- Why is it important to talk about “cure” for cancer patients?
- Definitions of cancer cure: clinical vs. statistical cure
- Three indicators: cure fraction, time to cure, median survival time of the “uncured”
- Methods to estimate indicators of statistical cure
- Interpretation of temporal trends using cure indicators

- Some results from international and national population-based studies
- Clinical and social implications of cancer cure

[Back](#)

## Session 21

### Practical 6 – Modelling statistical “cure”

- In this session, you will have the opportunity to do practical exercises based on the themes discussed in the accompanying lecture. A practical leader will facilitate the session, and faculty members will provide assistance. Solutions will be provided during the session.

[Back](#)

## Session 22

### Cancer survival – participants’ case studies

This session offers the opportunity for you to raise any question or practical problem in cancer survival research that you may have encountered, for open discussion with faculty and other participants.

[Back](#)

## Session 23

### Questions and answers from Day 4

- An informal question-and-answer session on any topic covered on the fourth day. All participants and faculty will be invited to contribute

[Back](#)

## Session 24

### Recent advances in cancer treatment

- Precision oncology: a new paradigm
- New treatments: immunotherapy, antibody-drug conjugates, small molecules
- Genomic testing in clinical practice
- Potential for (wider) disparities

[Back](#)

## Session 25

### Mortality-to-incidence ratio: not a valid proxy for cancer survival

- Mistaken in principle, misleading in practice
- Not comparable between cancers, countries or calendar periods, or by time since diagnosis
- Globocan and Global Burden of Disease estimates – extrapolation and models
- The  $(1 - M/I)$  ratio is indefensible as a proxy for cancer survival

[Back](#)

## Session 26

### International comparisons of cancer survival

- EUROCARE, CONCORD and other international collaborative studies
- “Low-resolution”, “high-resolution” and “patterns of care” studies
- Importance of centralised quality control and analysis

- Importance of appropriate life tables, statistical techniques and age-standardisation
- Impact of data quality and bias on the interpretation of international differences in survival
- Deployment of survival comparisons in national and international strategies for cancer control

[Back](#)

## **Session 27**

### **Cancer survival research and cancer policy – 2**

- Are cancer survival statistics of any use for public health and health policy?
- Confidentiality and consent in cancer registration
- Public health and policy impact of ethnic, socio-economic and international comparisons of cancer survival
- WHO policy on non-communicable diseases, the Sustainable Development Goals and the Global Initiative for Childhood Cancer, UN High-Level Meeting 2025

[Back](#)

## **Session 28**

### **Tools for survival analysis**

- Availability of software packages for the estimation of cancer survival *stns*, *strs*, SURV3, RELSURV, SEER\*Stat,... in Stata, SAS or R
- Implementation of survival analysis packages in public-use databases such as SEER\*Stat (USA) and the Cancer Information System (UK)
- Availability of life tables and other tools for survival analysis
- Residual questions about theoretical issues covered during the course

[Back to top of programme](#)

